Applied Genetic Technologies Corp. (AGTC) plans to launch a pivotal trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) by the end of this year, following strong positive six-month data from its ongoing Phase I/II trial. Normal retina pictured at left; retina affected by retinitis pigmentosa pictured at right. [AGTC]
Applied Genetic Technologies Corp. (AGTC) plans to launch a pivotal trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) by the end of this year, following strong positive six-month data from its ongoing Phase I/II trial . . .
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our privacy policy.